fingolimod hydrochloride has been researched along with Biliary Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azami, S; Konoeda, F; Sato, H | 1 |
| Adinolfi, LE; Alfieri, G; Dalla Mora, L; Lus, G; Marrone, A; Rainone, I; Rinaldi, L; Signoriello, E | 1 |
2 other study(ies) available for fingolimod hydrochloride and Biliary Cirrhosis
| Article | Year |
|---|---|
[A patient with relapsing-remitting multiple sclerosis who relapsed frequently and developed primary biliary cholangitis after pregnancy and discontinuation of fingolimod].
Topics: Adult; Autoantibodies; Biomarkers; Diagnosis, Differential; Female; Fingolimod Hydrochloride; Humans; Liver Cirrhosis, Biliary; Magnetic Resonance Imaging; Mitochondria; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Recurrence; Withholding Treatment | 2021 |
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
Topics: Adult; Cholagogues and Choleretics; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Multiple Sclerosis; Recurrence; Treatment Outcome; Ursodeoxycholic Acid; Withholding Treatment | 2014 |